REPL
Closed
Replimune Group Inc
9.15
-0.14 (-1.51%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 9.29
Day's Range: 9.12 - 9.7285
Send
sign up or login to leave a comment!
When Written:
16.36
Replimune Group Inc is a clinical-stage biotechnology company that focuses on the development of oncolytic immunotherapies for the treatment of cancer. The company's lead product candidate, RP1, is a replication-competent virus that is designed to selectively target and destroy cancer cells while stimulating an immune response against the tumor. Replimune's technology platform also includes other product candidates, such as RP2, RP3, and RP6, which are being developed for the treatment of various types of cancer. The company was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune Group Inc is publicly traded on the NASDAQ stock exchange under the ticker symbol "REPL".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








